In a bookshop I got an attention on an unusual topic in an unusual magazine, recently. The name of the magazine is called Forbes and topic is ‘How Novartis aims to reap billions of dollars in sales by focusing on big drug makers ignored rare diseases’.
'....When rheumatologist Timothy Wright joined Novartis (nyse: NVS - news - people ) in 2004 his first project was to rejuvenate an experimental arthritis drug. It was viewed lukewarmly in the lab because a similar drug from Amgen (nasdaq: AMGN - news - people ) had been a commercial flop.
Wright proposed testing the drug in patients with a disease so rare that some of his superiors had never heard of it: Muckle-Wells syndrome. At most a couple of thousand patients worldwide have the inherited disorder, which causes recurring fevers, rashes, joint pain and kidney damage. University researchers had just pinpointed a source: a bad gene that causes the body to produce an oversupply of interleukin-1, an immune system protein.....'
Please follow the link, for the complete article
Tips for opening the page:
after the link has open, please select the first one which goes as follows:
Big Bucks - Forbes.com
For years big drugmakers ignored rare diseases. Now Novartis aims to reap billions of dollars in sales by focusing on them.members.forbes.com/forbes/2007/0521/060.html - 57k - Cached - Similar pages
You can click either the main link itself or the link, 'cached'!
No comments:
Post a Comment